

### **ASX ANNOUNCEMENT**

31 July 2025

# **Expiry of Voluntary Escrow Restrictions**

Vitrafy Life Sciences Limited (ASX: VFY), (Vitrafy or Company) advises in accordance with ASX Listing Rule 3.10A, 5,205,280 fully paid ordinary shares that are currently subject to voluntary escrow, will cease to be escrowed on the day of the release of Vitrafy's audited accounts for the financial year ended 30 June 2025.

#### ### ENDS ###

This announcement is authorised by the Company Secretary of Vitrafy Life Sciences Limited.

#### For further information contact:

Investor and Media Relations
Simon Martin
Chief Financial Officer
investors@vitrafy.com

## **About Vitrafy**

Vitrafy has developed a proprietary range of smart cryopreservation hardware and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia, has an ISO13485 accredited Manufacturing Facility and Laboratory in Ballarat, Victoria and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.